Lisanti Capital Growth LLC raised its stake in shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 41.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 16,946 shares of the biopharmaceutical company’s stock after acquiring an additional 4,945 shares during the period. Lisanti Capital Growth LLC’s holdings in Portola Pharmaceuticals were worth $825,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in PTLA. Ameriprise Financial Inc. purchased a new stake in Portola Pharmaceuticals during the 2nd quarter valued at approximately $1,762,000. Northern Trust Corp grew its holdings in Portola Pharmaceuticals by 3.2% during the 2nd quarter. Northern Trust Corp now owns 635,998 shares of the biopharmaceutical company’s stock valued at $35,724,000 after buying an additional 19,719 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in Portola Pharmaceuticals by 11.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 35,675 shares of the biopharmaceutical company’s stock valued at $2,004,000 after buying an additional 3,530 shares in the last quarter. Numeric Investors LLC purchased a new stake in Portola Pharmaceuticals during the 2nd quarter valued at approximately $753,000. Finally, QS Investors LLC purchased a new stake in Portola Pharmaceuticals during the 2nd quarter valued at approximately $147,000. 87.29% of the stock is owned by institutional investors and hedge funds.

In related news, Director Henry Ward Wolff sold 12,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $47.00, for a total value of $564,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.50% of the company’s stock.

Portola Pharmaceuticals Inc (NASDAQ PTLA) opened at $44.41 on Friday. Portola Pharmaceuticals Inc has a fifty-two week low of $26.94 and a fifty-two week high of $67.10. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.31 and a quick ratio of 8.31. The firm has a market cap of $2,912.18, a price-to-earnings ratio of -10.28 and a beta of 1.18.

PTLA has been the subject of a number of research analyst reports. Oppenheimer reaffirmed a “buy” rating and set a $80.00 price objective on shares of Portola Pharmaceuticals in a report on Tuesday, November 7th. BidaskClub lowered shares of Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, December 7th. Zacks Investment Research lowered shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 4th. ValuEngine raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, William Blair reissued a “buy” rating on shares of Portola Pharmaceuticals in a report on Monday, January 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. Portola Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $70.65.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://theolympiareport.com/2018/02/10/portola-pharmaceuticals-inc-ptla-shares-bought-by-lisanti-capital-growth-llc.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Want to see what other hedge funds are holding PTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Portola Pharmaceuticals Inc (NASDAQ:PTLA).

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.